LAUSR

The platinum derivative cisplatin is widely used against many types of cancers effectively. However, cisplatin has limitations such as toxicity, resistances, and being thermally labile, non-volatile, and highly insoluble. To overcome these limitations, cisplatin with platinum(II) as metal centers needs to be modified to platinum(IV). Modification of platinum(IV) of cisplatin ligated to an organic ligand in the axial position could be a strategy to reduce its toxicity and increase the lifetime in blood when administered as an oral prodrug as an anti-cancer agent. The complex also has potential to be employed as a linker in bio-metal–organic frameworks (bioMOFs) synthesis and has good stability. Cisplatin-modified ligand also has a large size which can affect to the pore size on bioMOFs. Isonicotinic acid is a pyridine derivative with pyridine and carboxyl as an active group that can make coordination with metal ions on bioMOF assemblies. In this study, a simple and efficient method for the synthesis of a novel cisplatin-modified isonicotinic acid, nicoplatin, was reported. A substitution reaction possibly occurs on the axial position of oxoplatin by isonicotinic acid ligand. The obtained compound was fully characterized with FTIR, 1H-NMR, 13C-NMR, ESI–MS  and elemental analyses.Graphical abstract